A randomized, open-label, 3-way crossover study to assess the pharmacokinetic drug interactions between DS-8500a and a hypoglycemic agent (glimepiride or repaglinide) in Japanese healthy subjects
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2016
At a glance
- Drugs DS-8500 (Primary) ; Glimepiride; Repaglinide
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 25 Oct 2016 Status changed from active, no longer recruiting to completed.
- 25 Jul 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 03 Jun 2016 New trial record